{"id":391218,"date":"2015-12-07T00:00:00","date_gmt":"2015-12-07T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/pforus2515-biopharma-market-access-dynamics-in-obesity-physician-payer-forum-us-2015\/"},"modified":"2026-04-15T23:26:44","modified_gmt":"2026-04-15T23:26:44","slug":"pforus2515-biopharma-market-access-dynamics-in-obesity-physician-payer-forum-us-2015","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/pforus2515-biopharma-market-access-dynamics-in-obesity-physician-payer-forum-us-2015\/","title":{"rendered":"Market Access Dynamics in Obesity | Physician &#038; Payer Forum | US | 2015"},"content":{"rendered":"<p>Four novel prescription weight-loss agents have\u00a0launched in the United States since 2012: Vivus\u2019s Qsymia (phentermine\/topiramate ER), Arena Pharmaceuticals\/Eisai\u2019s Belviq (lorcaserin), Orexigen Therapeutic\/Takeda Pharmaceutical\u2019s Contrave (naltrexone SR\/bupropion SR), and Novo Nordisk\u2019s Saxenda (liraglutide 3 mg).\u00a0However, therapeutic options remain limited, despite the high prevalence of overweight and obesity in the United States and increasing awareness of this public health issue. The reimbursement environment for pharmaceutical obesity treatments is challenging; the high prevalence of obesity has restricted access to medical treatments because healthcare budgets cannot afford widespread use of expensive new medications. In time though, the increase in weight-related comorbidities and complications, particularly type 2 diabetes, will pressure insurers\u2019 healthcare resources. Consequently, the market opportunity for a safe and well-tolerated pharmaceutical agent that can\u00a0induce satisfactory weight loss is considerable, but drug developers will need to be aware of the unique dynamics of the of the obesity market to ensure access, secure reimbursement, maximize uptake, and realize the commercial potential.<\/p>\n","protected":false},"template":"","class_list":["post-391218","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-cardiovascular","biopharma-geography-us","biopharma-date-717"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391218","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391218\/revisions"}],"predecessor-version":[{"id":576909,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391218\/revisions\/576909"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=391218"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}